Skip to content

Effects of Microbiological and Immunological Factors on the Lower Urinary Tract

RecruitingNCT07494864
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Millions of patients of all ages suffer worldwide from diverse urinary pathologies, such as lower urinary tract (LUT) dysfunction, bladder pain syndrome, urinary tract infections (UTIs), or bladder cancer. The research project investigates the interplay between the bladder and the microbiome. The goal is to evaluate the association of microbiological and immunological factors with lower urinary tract health in humans.

Study details

Official title
Effects of Microbiological and Immunological Factors on the Lower Urinary Tract
Conditions
  • Asymptomatic Bacteriuria in Subjects Not Requiring Assisted Bladder Emptying
  • Asymptomatic Bacteriuria in Subjects Relying on Some Type of Catheter
  • Recurrent Non-catheter Associated UTIs
  • Acute Catheter-associated UTI (CAUTI)
  • Recurrent Catheter-associated UTI (CAUTI)
  • Chronic Pelvic Pain
  • Non-neurogenic Overactive Bladder Syndrome / LUT Symptoms
  • Non-muscle-invasive Bladder Cancer
Sponsor
University of Zurich
Collaborators
Kessler Group; Rätsch Group; Slack Group; Boyman Group; Sunagawa Group; Zamboni Group; Loessner Group; McKinney Group; Nexus; Research Group Dirk Bumann; Research Group Christoph Dehio
Start date
2023-06-01
Primary completion
2026-11-30
Sex
All
Age range
from 18 Years
Healthy volunteers
true
Results posted
No results posted in this snapshot
Countries
Switzerland
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
General inclusion criteria: * Women and men aged ≥ 18 years old * Able to give informed consent for participation in the study * Willing to adhere to the study protocol for the whole trial period * Willing to undergo repetitive in-and-out single catheterization Specific inclusion criteria for the different study arms Arm I: Healthy controls Arm II: Asymptomatic bacteriuria in subjects not requiring assisted bladder emptying Arm III: Asymptomatic bacteriuria in subjects relying on some type of catheter for bladder emptying Arm IV: Acute non-catheter associated UTIs Arm V: Recurrent non-catheter associated UTIs Arm VI: Acute catheter-associated UTI Arm VII: Recurrent catheter-associated UTI Arm VIII: Chronic pelvic pain Arm IX: Non-neurogenic overactive bladder syndrome Arm X: Non-muscle-invasive bladder cancer Exclusion Criteria: * Current antibiotic treatment or antibiotic treatment within the last 21 days (except for study arms IV-VII) * UTI secondary to diagnosed treatable pathologies (i.e., bladder stones, enterovesical fistula etc.) and requiring specific therapy Current therapies for preventing UTIs (e.g., urine acidification, phytotherapy) or such therapies within the last 21 days (except for study arms IV-VII) * Deterioration of the upper urinary tract requiring medical intervention * Immunomodulatory therapies (apart from routine vaccination) * Congenital or acquired malformations of the LUT (study arm I only) * Immunosuppressant therapy (study arm I only) * Need for antiviral medication (study arm I only) * Significant pre-existing or current severe systemic disease such as lung, liver (exception: history of uncomplicated Hepatitis A), gastrointestinal, cardiac, immunodeficiency (including anamnestic known AIDS) or kidney disease; or active malignancy (except from bladder cancer) or any other condition as determined by history or laboratory investigation that could cause susceptibility to infections. * Presence of any unstable medical or psychiatric condition (defined by the Diagnostic and Statistical Manual of Mental Disorders, Edition 4 (DSM-IV)) that could reasonably have been expected to subject the patient to unwarranted risk from participation in the study or result in a significant deterioration of the patient's clinical course. * Drug/alcohol dependence (as defined by DSM-IV) any time during the 6 months preceding study entry. * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and …

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07494864